Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 2
2008 3
2009 1
2010 3
2011 3
2012 2
2013 1
2016 1
2017 6
2018 3
2019 2
2020 14
2021 13
2022 14
2023 7
2024 6
2025 7
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Ageing hallmarks exhibit organ-specific temporal signatures.
Schaum N, Lehallier B, Hahn O, Pálovics R, Hosseinzadeh S, Lee SE, Sit R, Lee DP, Losada PM, Zardeneta ME, Fehlmann T, Webber JT, McGeever A, Calcuttawala K, Zhang H, Berdnik D, Mathur V, Tan W, Zee A, Tan M; Tabula Muris Consortium; Pisco AO, Karkanias J, Neff NF, Keller A, Darmanis S, Quake SR, Wyss-Coray T. Schaum N, et al. Nature. 2020 Jul;583(7817):596-602. doi: 10.1038/s41586-020-2499-y. Epub 2020 Jul 15. Nature. 2020. PMID: 32669715 Free PMC article.
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Kollef MH, Nováček M, Kivistik Ü, Réa-Neto Á, Shime N, Martin-Loeches I, Timsit JF, Wunderink RG, Bruno CJ, Huntington JA, Lin G, Yu B, Butterton JR, Rhee EG. Kollef MH, et al. Among authors: yu b. Lancet Infect Dis. 2019 Dec;19(12):1299-1311. doi: 10.1016/S1473-3099(19)30403-7. Epub 2019 Sep 25. Lancet Infect Dis. 2019. PMID: 31563344 Clinical Trial.
Molecular hallmarks of heterochronic parabiosis at single-cell resolution.
Pálovics R, Keller A, Schaum N, Tan W, Fehlmann T, Borja M, Kern F, Bonanno L, Calcuttawala K, Webber J, McGeever A; Tabula Muris Consortium; Luo J, Pisco AO, Karkanias J, Neff NF, Darmanis S, Quake SR, Wyss-Coray T. Pálovics R, et al. Nature. 2022 Mar;603(7900):309-314. doi: 10.1038/s41586-022-04461-2. Epub 2022 Mar 2. Nature. 2022. PMID: 35236985 Free PMC article.
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. Chou J, et al. Among authors: yu b. Cancer Res. 2023 Jan 18;83(2):301-315. doi: 10.1158/0008-5472.CAN-22-1433. Cancer Res. 2023. PMID: 36351060 Free PMC article.
A molecular cell atlas of mouse lemur, an emerging model primate.
Tabula Microcebus Consortium; Ezran C, Liu S, Chang S, Ming J, Botvinnik O, Penland L, Tarashansky A, de Morree A, Travaglini KJ, Zhao J, Wang G, Hasegawa K, Sin H, Sit R, Okamoto J, Sinha R, Zhang Y, Karanewsky CJ, Pendleton JL, Morri M, Perret M, Aujard F, Stryer L, Artandi S, Fuller MT, Weissman IL, Rando TA, Ferrell JE Jr, Wang B, De Vlaminck I, Yang C, Casey KM, Albertelli MA, Pisco AO, Karkanias J, Neff N, Wu AR, Quake SR, Krasnow MA. Tabula Microcebus Consortium, et al. Nature. 2025 Aug;644(8075):173-184. doi: 10.1038/s41586-025-09113-9. Epub 2025 Jul 30. Nature. 2025. PMID: 40739356 Free PMC article.
Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.
Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A. Aggarwal R, et al. Among authors: yu b. Clin Cancer Res. 2025 Sep 15;31(18):3854-3863. doi: 10.1158/1078-0432.CCR-25-1211. Clin Cancer Res. 2025. PMID: 40689871 Free PMC article. Clinical Trial.
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study.
Minocha M, Thompson CG, Murphy A, Zhou Y, Brandl C, Parkes A, Chen X, Yu B, Martinez P, Houk BE. Minocha M, et al. Among authors: yu b. Clin Pharmacokinet. 2024 Dec;63(12):1757-1768. doi: 10.1007/s40262-024-01451-7. Epub 2024 Nov 26. Clin Pharmacokinet. 2024. PMID: 39589690 Clinical Trial.
Mouse lemur cell atlas informs primate genes, physiology and disease.
Ezran C, Liu S, Chang S, Ming J, Guethlein LA, Wang MFZ, Dehghannasiri R, Olivieri J, Frank HK, Tarashansky A, Koh W, Jing Q, Botvinnik O, Antony J; Tabula Microcebus Consortium; Pisco AO, Karkanias J, Yang C, Ferrell JE Jr, Boyd SD, Parham P, Long JZ, Wang B, Salzman J, De Vlaminck I, Wu AR, Quake SR, Krasnow MA. Ezran C, et al. Nature. 2025 Aug;644(8075):185-196. doi: 10.1038/s41586-025-09114-8. Epub 2025 Jul 30. Nature. 2025. PMID: 40739355 Free PMC article.
Bacterial Evolution in High-Osmolarity Environments.
Cesar S, Anjur-Dietrich M, Yu B, Li E, Rojas E, Neff N, Cooper TF, Huang KC. Cesar S, et al. Among authors: yu b. mBio. 2020 Aug 4;11(4):e01191-20. doi: 10.1128/mBio.01191-20. mBio. 2020. PMID: 32753494 Free PMC article.
ROCK as a therapeutic target for ischemic stroke.
Sladojevic N, Yu B, Liao JK. Sladojevic N, et al. Among authors: yu b. Expert Rev Neurother. 2017 Dec;17(12):1167-1177. doi: 10.1080/14737175.2017.1395700. Epub 2017 Oct 30. Expert Rev Neurother. 2017. PMID: 29057688 Free PMC article. Review.
Ultra-deep Sequencing of Hadza Hunter-Gatherers Recovers Vanishing Gut Microbes.
Merrill BD, Carter MM, Olm MR, Dahan D, Tripathi S, Spencer SP, Yu B, Jain S, Neff N, Jha AR, Sonnenburg ED, Sonnenburg JL. Merrill BD, et al. Among authors: yu b. bioRxiv [Preprint]. 2022 Oct 6:2022.03.30.486478. doi: 10.1101/2022.03.30.486478. bioRxiv. 2022. Update in: Cell. 2023 Jul 6;186(14):3111-3124.e13. doi: 10.1016/j.cell.2023.05.046. PMID: 36238714 Free PMC article. Updated. Preprint.
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Martin-Loeches I, Timsit JF, Kollef MH, Wunderink RG, Shime N, Nováček M, Kivistik Ü, Réa-Neto Á, Bruno CJ, Huntington JA, Lin G, Jensen EH, Motyl M, Yu B, Gates D, Butterton JR, Rhee EG. Martin-Loeches I, et al. Among authors: yu b. J Antimicrob Chemother. 2022 Mar 31;77(4):1166-1177. doi: 10.1093/jac/dkab494. J Antimicrob Chemother. 2022. PMID: 35022730 Free PMC article. Clinical Trial.
Feasibility and Methodology of a Pilot Free Blood Pressure Monitoring and Follow-Up Program at Two Free Clinics.
Mikos G, Yu B, Balbin J, Martinez-Reyes L, Tang JM, Lieu BN, Tran E, Xue A, Lee J, Wary N, Franke C, Panyanouvong N, Chaclan MJ, Chang TH, Chen C, Guo MY, Harvell K, Horan R, Johnson NA, Kim A, Liu E, Liu L, Nuñez-Perez P, Quig M, Sanyal A, Sharma K, Wang I, Wang K, Filsoof A, Charon M, Montacute T, Singh B. Mikos G, et al. Among authors: yu b. J Prim Care Community Health. 2024 Jan-Dec;15:21501319241278836. doi: 10.1177/21501319241278836. J Prim Care Community Health. 2024. PMID: 39269685 Free PMC article.
Association of Body Mass Index With Outcomes Among Patients With Head and Neck Cancer Treated With Chemoradiotherapy.
Ma SJ, Khan M, Chatterjee U, Santhosh S, Hashmi M, Gill J, Yu B, Iovoli A, Farrugia M, Wooten K, Gupta V, McSpadden R, Yu H, Kuriakose MA, Markiewicz MR, Al-Afif A, Hicks WL Jr, Seshadri M, Ray AD, Repasky E, Singh AK. Ma SJ, et al. Among authors: yu b. JAMA Netw Open. 2023 Jun 1;6(6):e2320513. doi: 10.1001/jamanetworkopen.2023.20513. JAMA Netw Open. 2023. PMID: 37368400 Free PMC article.
Impact of Patient-Reported Outcome Measurement in Heart Failure Clinic on Clinician Health Status Assessment and Patient Experience: A Substudy of the PRO-HF Trial.
Sandhu AT, Zheng J, Kalwani NM, Gupta A, Calma J, Skye M, Lan R, Yu B, Spertus JA, Heidenreich PA. Sandhu AT, et al. Among authors: yu b. Circ Heart Fail. 2023 Feb;16(2):e010280. doi: 10.1161/CIRCHEARTFAILURE.122.010280. Epub 2022 Nov 5. Circ Heart Fail. 2023. PMID: 36334312 Free PMC article. Clinical Trial.
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Kollef MH, Timsit JF, Martin-Loeches I, Wunderink RG, Huntington JA, Jensen EH, Yu B, Bruno CJ. Kollef MH, et al. Among authors: yu b. Crit Care. 2022 Dec 1;26(1):373. doi: 10.1186/s13054-022-04192-w. Crit Care. 2022. PMID: 36457059 Free PMC article. Clinical Trial.
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
Paterson DL, Bassetti M, Motyl M, Johnson MG, Castanheira M, Jensen EH, Huntington JA, Yu B, Wolf DJ, Bruno CJ. Paterson DL, et al. Among authors: yu b. J Antimicrob Chemother. 2022 Aug 25;77(9):2522-2531. doi: 10.1093/jac/dkac184. J Antimicrob Chemother. 2022. PMID: 35781341 Free article. Clinical Trial.
Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation.
Ma SJ, Yu H, Khan M, Yu B, Santhosh S, Chatterjee U, Gill J, Iovoli A, Farrugia M, Wooten K, Gupta V, McSpadden R, Kuriakose MA, Markiewicz MR, Al-Afif A, Hicks WL Jr, Platek ME, Seshadri M, Ray AD, Repasky E, Singh AK. Ma SJ, et al. Among authors: yu b. Oral Oncol. 2022 Oct;133:106054. doi: 10.1016/j.oraloncology.2022.106054. Epub 2022 Aug 5. Oral Oncol. 2022. PMID: 35933937 Free PMC article.
Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).
Huntington JA, Yu B, Li L, Jensen E, Bruno C, Boakye M, Zhang Z, Gao W, Feng HP, Rhee E. Huntington JA, et al. Among authors: yu b. Antimicrob Agents Chemother. 2020 Nov 17;64(12):e00731-20. doi: 10.1128/AAC.00731-20. Print 2020 Nov 17. Antimicrob Agents Chemother. 2020. PMID: 32988827 Free PMC article. Clinical Trial.
Association of Pack-Years of Cigarette Smoking With Survival and Tumor Progression Among Patients Treated With Chemoradiation for Head and Neck Cancer.
Ma SJ, Yu H, Yu B, Waldman O, Khan M, Chatterjee U, Santhosh S, Gill J, Iovoli AJ, Farrugia M, Shevorykin A, Carl E, Wooten K, Gupta V, McSpadden R, Kuriakose MA, Markiewicz MR, Al-Afif A, Hicks WL Jr, Platek ME, Seshadri M, Sheffer C, Warren GW, Singh AK. Ma SJ, et al. Among authors: yu b. JAMA Netw Open. 2022 Dec 1;5(12):e2245818. doi: 10.1001/jamanetworkopen.2022.45818. JAMA Netw Open. 2022. PMID: 36480200 Free PMC article.
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
Martin-Loeches I, Shorr AF, Wunderink RG, Kollef MH, Timsit JF, Yu B, Huntington JA, Jensen E, Bruno CJ. Martin-Loeches I, et al. Among authors: yu b. Ann Intensive Care. 2023 Feb 11;13(1):8. doi: 10.1186/s13613-022-01084-8. Ann Intensive Care. 2023. PMID: 36773112 Free PMC article.
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Timsit JF, Huntington JA, Wunderink RG, Shime N, Kollef MH, Kivistik Ü, Nováček M, Réa-Neto Á, Martin-Loeches I, Yu B, Jensen EH, Butterton JR, Wolf DJ, Rhee EG, Bruno CJ. Timsit JF, et al. Among authors: yu b. Crit Care. 2021 Aug 11;25(1):290. doi: 10.1186/s13054-021-03694-3. Crit Care. 2021. PMID: 34380538 Free PMC article. Clinical Trial.
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Johnson MG, Bruno C, Castanheira M, Yu B, Huntington JA, Carmelitano P, Rhee EG, De Anda C, Motyl M. Johnson MG, et al. Among authors: yu b. Int J Antimicrob Agents. 2021 Mar;57(3):106278. doi: 10.1016/j.ijantimicag.2021.106278. Epub 2021 Jan 9. Int J Antimicrob Agents. 2021. PMID: 33434676 Free article. Clinical Trial.
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
Petrak RM, Skorodin NC, Van Hise NW, Fliegelman RM, Pinsky J, Didwania V, Anderson M, Diaz M, Shah K, Chundi VV, Hines DW, Harting BP, Sidwha K, Yu B, Brune P, Owaisi A, Beezhold D, Kent J, Vais D, Han A, Gowda N, Sahgal N, Silverman J, Stake J, Nepomuceno J, Heddurshetti R. Petrak RM, et al. Among authors: yu b. Clin Transl Sci. 2021 Nov;14(6):2146-2151. doi: 10.1111/cts.12894. Epub 2021 Oct 27. Clin Transl Sci. 2021. PMID: 32918792 Free PMC article.
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
Caro L, Nicolau DP, De Waele JJ, Kuti JL, Larson KB, Gadzicki E, Yu B, Zeng Z, Adedoyin A, Rhee EG. Caro L, et al. Among authors: yu b. J Antimicrob Chemother. 2020 Jun 1;75(6):1546-1553. doi: 10.1093/jac/dkaa049. J Antimicrob Chemother. 2020. PMID: 32211756 Free PMC article. Clinical Trial.
Nasopharyngectomy and surgical margin status: a survival analysis.
Vlantis AC, Tsang RK, Yu BK, Kam MK, Tong MC, Lo PS, van Hasselt CA. Vlantis AC, et al. Among authors: yu bk. Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1296-301. doi: 10.1001/archotol.133.12.1296. Arch Otolaryngol Head Neck Surg. 2007. PMID: 18086975
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
Dimopoulos MA, Schjesvold F, Fu C, Hartley-Brown MA, Gomez C, Reece D, Mikala G, Alkharabsheh O, Parrish C, de Queiroz Crusoé E, Gálvez K, Idrobo H, White D, Gupta R, Lee C, Liu CJ, Quach H, Wang Y, Cerchione C, Forsyth C, Hungria V, Kalaskar P, Graklanov V, Ho PJ, Klaiber-Hakimi M, Kwong YL, Louzada M, Mazumder A, Miles O, Nagarajan C, Prasad SVSS, Raab MS, Varga G, von der Heyde E, Xia Z, Ochoa PA, Oriol A, Yuda J, Kuroda J, Gong J, Zhou Z, Maciag P, Yu B, Rocci A, Koo P, Katz J, Richardson PG; SUCCESSOR-2 Trial Investigators. Dimopoulos MA, et al. Among authors: yu b. Lancet. 2026 Jun 14:S0140-6736(26)01088-3. doi: 10.1016/S0140-6736(26)01088-3. Online ahead of print. Lancet. 2026. PMID: 42289183